Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs Bristol-Myers Squibb Co — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $11.12, while Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | BMY | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $15.75 | $65.89 |
52-Week Low | $9.98 | $42.60 |
Market Cap | — | $129.94B |
Enterprise Value | — | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $11.24, down 3.27% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock faces critical support at $11 and resistance at $12. Recent news highlights consistent weekly dividend distributions from YieldMax ETFs, though analyst reports express concerns about NAV erosion despite the high yield strategy.
The outlook for AMZY is mixed; the bullish technical trend and high dividend yield present income opportunities, but fundamental risks include potential NAV erosion and underperformance relative to Amazon. Investors should weigh the attractive weekly distributions against the sustainability of the option income strategy and amplified downside risks highlighted by analysts.
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
